15/09/2017 – Magos AI, the first ever blockchain-based prediction software, has already gathered almost 3000 ETH in its Initial Coin Offering (ICO).
Sophia Genetics, a Lausanne, Switzerland-based data-driven medicine company, closed a $30m Series D funding round.
Amal Therapeutics, a Geneva, Switzerland-based biotech startup developing novel, peptide-based therapeutic cancer vaccines, raised €8M in first closing of Series B funding round.
Everyday, we hear experts saying that Artificial Intelligence is going to transform the world we live in, the way we work, we buy products, spend our spare time, etc., thanks to its unbelievable learning capabilities.
Virometix, a Schlieren, Switzerland-based biotechnology company, raised CHF1.2m in in an extension to its recent Series A financing round.
elium (formerly known as Knowledge Plaza), a Mont-St-Guibert, Belgium-based collaborative platform for knowledge-based organizations, closed a €4M Series A funding round.
Artificial Intelligence (AI) is bound to transform the world we live in, as some believe that in the future we won’t even have to work anymore, as production will be at an all-time high thanks to AI agents.
Astrocast (FKA Else), a Switzerland-based startup developing a Low Earth Orbit (LEO) nanosatellite constellation, closed $3M in seed funding.
Muume Group AG, a Cham, Switzerland-based fintech company, completed its over 6m Swiss francs Series B round of funding.
24/08/2017 – Zurich, Switzerland – Magos, a blockchain powered complex forecasting platform, has just launched its crowdsale.
Breadwallet, a Switzerland-based developer of a decentralized iOS wallet, closed a new funding round, bringing its total investment to $7m.
SK Capital Partners, a private investment firm with a focus on the specialty materials, chemicals and pharmaceutical sectors, is reinvesting in Archroma, a Basel, Switzerland-based color and specialty chemicals company.
Tezos Foundation, the Swiss maker of a decentralized blockchain that facilitates formal verification, a technique which mathematically proves the correctness of the code governing transactions and boosts the security of smart contracts, announced a $50m venture capital commitment.
Vicarius Pharma, a Kuessnacht, Switzerland—based provider of a novel approach for U.S.-based bio-pharmaceutical companies to commercialize their first asset in European markets, secured a CHF21m (approx. $21.8m) in Series A financing.
Roivant Sciences, a global healthcare company, raised $1.1 billion in equity funding.